Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Lexaria Bioscience Corp.
Lexaria Bioscience Corp. News
Jun 23, 2025 - accessnewswire.com
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Jun 23, 2025 - thenewswire.com
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Jun 11, 2025 - accessnewswire.com
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Jun 11, 2025 - thenewswire.com
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Lexaria Bioscience Corp. Quantitative Score
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Lexaria Bioscience Corp. Financials
Table Compare
Compare LEXX metrics with: | |||
|---|---|---|---|
Earnings & Growth | LEXX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LEXX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LEXX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LEXX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Lexaria Bioscience Corp. Income
Lexaria Bioscience Corp. Balance Sheet
Lexaria Bioscience Corp. Cash Flow
Lexaria Bioscience Corp. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Lexaria Bioscience Corp. Executives
| Name | Role |
|---|---|
| Mr. John M. Docherty M.Sc. | Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director |
| Mr. Richard C. Christopher | Chief Executive Officer & Director |
| Ms. Kristin Hamilton | Director of Operations |
| Mr. Michael Shankman CPA | Chief Financial Officer |
| Dr. C. Michael Gibson M.D., M.S. | Chief Medical Advisor & Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. John M. Docherty M.Sc. | Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director | Male | 1969 | 329.34K |
| Mr. Richard C. Christopher | Chief Executive Officer & Director | Male | 1970 | 5K |
| Ms. Kristin Hamilton | Director of Operations | Female | -- | |
| Mr. Michael Shankman CPA | Chief Financial Officer | Male | 1960 | -- |
| Dr. C. Michael Gibson M.D., M.S. | Chief Medical Advisor & Member of Scientific Advisory Board | -- |
Lexaria Bioscience Corp. Insider Trades
| Date | 15 May |
| Name | CHRISTOPHER RICHARD |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 150000 |
| Date | 15 May |
| Name | BUNKA CHRISTOPHER |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 11000 |
| Date | 15 May |
| Name | Carle Vanessa |
| Role | Secretary |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 15000 |
| Date | 15 May |
| Name | DOCHERTY JOHN MARTIN |
| Role | President |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 150000 |
| Date | 15 May |
| Name | Shankman Michael Elliot |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 50000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 May | CHRISTOPHER RICHARD | Chief Executive Officer | Acquired | A-Award | 150000 |
| 15 May | BUNKA CHRISTOPHER | Director | Acquired | A-Award | 11000 |
| 15 May | Carle Vanessa | Secretary | Acquired | A-Award | 15000 |
| 15 May | DOCHERTY JOHN MARTIN | President | Acquired | A-Award | 150000 |
| 15 May | Shankman Michael Elliot | Chief Financial Officer | Acquired | A-Award | 50000 |